Nanoparticle diffusion in spontaneously expectorated sputum as a biophysical tool to probe disease severity in COPD

Perturbations in airway mucus properties contribute to lung function decline in patients with chronic obstructive pulmonary disease (COPD). While alterations in bulk mucus rheology have been widely explored, microscopic mucus properties that directly impact on the dynamics of microorganisms and immune cells in the COPD lungs are yet to be investigated. We hypothesised that a tightened mesh structure of spontaneously expectorated mucus (i.e. sputum) would contribute to increased COPD disease severity. Here, we investigated whether the mesh size of COPD sputum, quantified by muco-inert nanoparticle (MIP) diffusion, correlated with sputum composition and lung function measurements. The microstructure of COPD sputum was assessed based on the mean squared displacement (MSD) of variously sized MIPs measured by multiple particle tracking. MSD values were correlated with sputum composition and spirometry. In total, 33 samples collected from COPD or non-COPD individuals were analysed. We found that 100 nm MIPs differentiated microstructural features of COPD sputum. The mobility of MIPs was more hindered in sputum samples from patients with severe COPD, suggesting a tighter mucus mesh size. Specifically, MSD values inversely correlated with lung function. These findings suggest that sputum microstructure may serve as a novel risk factor for COPD progression and severity. Microstructural properties of COPD sputum probed by motility of 100 nm muco-inert particles correlate with disease severity characterised by pulmonary lung function http://bit.ly/2WOf7yF

[1]  E. Hoffman,et al.  Airway Mucin Concentration as a Marker of Chronic Bronchitis , 2017, The New England journal of medicine.

[2]  Benjamin C. Tang,et al.  Nanoparticles that do not adhere to mucus provide uniform and long-lasting drug delivery to airways following inhalation , 2017, Science Advances.

[3]  Gregg A. Duncan,et al.  The Mucus Barrier to Inhaled Gene Therapy. , 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

[4]  Gregg A. Duncan,et al.  Microstructural alterations of sputum in cystic fibrosis lung disease. , 2016, JCI insight.

[5]  P. Gibson,et al.  Neutrophil extracellular traps are associated with inflammation in chronic airway disease , 2016, Respirology.

[6]  Laura M Ensign,et al.  PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. , 2016, Advanced drug delivery reviews.

[7]  J. Wedzicha,et al.  The Presence of Chronic Mucus Hypersecretion across Adult Life in Relation to Chronic Obstructive Pulmonary Disease Development. , 2016, American journal of respiratory and critical care medicine.

[8]  Ajit Varki,et al.  Acidic pH increases airway surface liquid viscosity in cystic fibrosis. , 2016, The Journal of clinical investigation.

[9]  J. Wedzicha,et al.  Impact of Prolonged Exacerbation Recovery in Chronic Obstructive Pulmonary Disease. , 2015, American journal of respiratory and critical care medicine.

[10]  Benjamin S Schuster,et al.  Particle tracking in drug and gene delivery research: State-of-the-art applications and methods. , 2015, Advanced drug delivery reviews.

[11]  B. Qaqish,et al.  The Relationship of Mucus Concentration (Hydration) to Mucus Osmotic Pressure and Transport in Chronic Bronchitis. , 2015, American journal of respiratory and critical care medicine.

[12]  J. S. Suk,et al.  Highly compacted biodegradable DNA nanoparticles capable of overcoming the mucus barrier for inhaled lung gene therapy , 2015, Proceedings of the National Academy of Sciences.

[13]  M. Litt,et al.  Mucus rheology and mucociliary clearance: Normal physiologic state. , 2015, The American review of respiratory disease.

[14]  S. Hazen,et al.  Oxidation increases mucin polymer cross-links to stiffen airway mucus gels , 2015, Science Translational Medicine.

[15]  Ting-Yu Shih,et al.  Brain-Penetrating Nanoparticles Improve Paclitaxel Efficacy in Malignant Glioma Following Local Administration , 2014, ACS nano.

[16]  Scott A. McKinley,et al.  A Biophysical Basis for Mucus Solids Concentration as a Candidate Biomarker for Airways Disease , 2014, PloS one.

[17]  P. Abete,et al.  A New Method to Improve the Clinical Evaluation of Cystic Fibrosis Patients by Mucus Viscoelastic Properties , 2014, PloS one.

[18]  J. Hanes,et al.  The microstructure and bulk rheology of human cervicovaginal mucus are remarkably resistant to changes in pH. , 2013, Biomacromolecules.

[19]  M. Schlesser,et al.  Chronic bronchitis in COPD patients is associated with increased risk of exacerbations: a cross‐sectional multicentre study , 2013, International journal of clinical practice.

[20]  Bradley S. Turner,et al.  The Influence of Mucus Microstructure and Rheology in Helicobacter pylori Infection , 2013, Front. Immunol..

[21]  P. Kirkham,et al.  Oxidative stress in COPD. , 2013, Chest.

[22]  P. McDonnell,et al.  Nanoparticle diffusion in, and microrheology of, the bovine vitreous ex vivo. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[23]  G. Woodworth,et al.  Nanoparticle diffusion in respiratory mucus from humans without lung disease. , 2013, Biomaterials.

[24]  E. Arias,et al.  Deaths: preliminary data for 2011. , 2012, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.

[25]  C. W. Davis,et al.  CFTR, mucins, and mucus obstruction in cystic fibrosis. , 2012, Cold Spring Harbor perspectives in medicine.

[26]  Elizabeth Nance,et al.  A Dense Poly(Ethylene Glycol) Coating Improves Penetration of Large Polymeric Nanoparticles Within Brain Tissue , 2012, Science Translational Medicine.

[27]  J. S. Suk,et al.  Mucus Penetrating Nanoparticles: Biophysical Tool and Method of Drug and Gene Delivery , 2012, Advanced materials.

[28]  A. Vestri,et al.  Analysis of Sputum Markers in the Evaluation of Lung Inflammation and Functional Impairment in Symptomatic Smokers and COPD Patients , 2011, Disease markers.

[29]  O. Mert,et al.  Drug carrier nanoparticles that penetrate human chronic rhinosinusitis mucus. , 2011, Biomaterials.

[30]  J. Hokanson,et al.  The chronic bronchitic phenotype of COPD: an analysis of the COPDGene Study. , 2011, Chest.

[31]  J. Fahy,et al.  Airway mucus function and dysfunction. , 2010, The New England journal of medicine.

[32]  J. Wedzicha,et al.  Susceptibility to exacerbation in chronic obstructive pulmonary disease. , 2010, The New England journal of medicine.

[33]  V. Brusasco,et al.  Revisited role for mucus hypersecretion in the pathogenesis of COPD , 2010, European Respiratory Review.

[34]  S. Young,et al.  Macrorheology of cystic fibrosis, chronic obstructive pulmonary disease & normal sputum , 2009, Respiratory research.

[35]  Michael P Boyle,et al.  The penetration of fresh undiluted sputum expectorated by cystic fibrosis patients by non-adhesive polymer nanoparticles. , 2009, Biomaterials.

[36]  Nicolas Roche,et al.  Cough and sputum production are associated with frequent exacerbations and hospitalizations in COPD subjects. , 2009, Chest.

[37]  Denis Wirtz,et al.  Micro- and macrorheology of mucus. , 2009, Advanced drug delivery reviews.

[38]  Kyubo Kim,et al.  Mucus hypersecretion in asthma: causes and effects , 2009, Current opinion in pulmonary medicine.

[39]  P. Paggiaro,et al.  Biological Markers in Induced Sputum of Patients with Different Phenotypes of Chronic Airway Obstruction , 2008, Respiration.

[40]  D. Rogers Mucus hypersecretion in chronic obstructive pulmonary disease. , 2008, Novartis Foundation symposium.

[41]  A L Hansell,et al.  Proportional classifications of COPD phenotypes , 2008, Thorax.

[42]  P. Paré,et al.  Survival after lung volume reduction in chronic obstructive pulmonary disease: insights from small airway pathology. , 2007, American journal of respiratory and critical care medicine.

[43]  Justin Hanes,et al.  Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus , 2007, Proceedings of the National Academy of Sciences.

[44]  S. Ramsey,et al.  Chronic obstructive pulmonary disease, risk factors, and outcome trials: comparisons with cardiovascular disease. , 2006, Proceedings of the American Thoracic Society.

[45]  Scott H Randell,et al.  Effective mucus clearance is essential for respiratory health. , 2006, American journal of respiratory cell and molecular biology.

[46]  Amir Sharafkhaneh,et al.  Airway mucus: From production to secretion. , 2006, American journal of respiratory cell and molecular biology.

[47]  H. Danahay,et al.  Epithelial mucus-hypersecretion and respiratory disease. , 2005, Current drug targets. Inflammation and allergy.

[48]  S. Randell,et al.  Reduced Three-Dimensional Motility in Dehydrated Airway Mucus Prevents Neutrophil Capture and Killing Bacteria on Airway Epithelial Surfaces1 , 2005, The Journal of Immunology.

[49]  P. Janmey,et al.  Elastic contributions dominate the viscoelastic properties of sputum from cystic fibrosis patients. , 2004, Biophysical chemistry.

[50]  I. Adcock,et al.  Mucin expression in peripheral airways of patients with chronic obstructive pulmonary disease , 2004, Histopathology.

[51]  P. Paré,et al.  The nature of small-airway obstruction in chronic obstructive pulmonary disease. , 2004, The New England journal of medicine.

[52]  M. Knowles,et al.  Mucus clearance as a primary innate defense mechanism for mammalian airways. , 2002, The Journal of clinical investigation.

[53]  Denis Wirtz,et al.  Particle Tracking Microrheology of Complex Fluids , 1997 .

[54]  A Bast,et al.  Oxidative stress in chronic obstructive pulmonary disease. Oxidative Stress Study Group. , 1997, American journal of respiratory and critical care medicine.

[55]  J. Vestbo,et al.  Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group. , 1996, American journal of respiratory and critical care medicine.

[56]  Dl Hoyert,et al.  National Vital Statistics Reports NCHS.pdf , 2012 .

[57]  Q. Hamid,et al.  Mucin overproduction in chronic inflammatory lung disease. , 2006, Canadian respiratory journal.

[58]  L. Allegra,et al.  Identification of subpopulations of bronchitic patients for suitable therapy by a dynamic rheological test. , 1989, International journal of clinical pharmacology research.